Publications by authors named "Justo Ortega"
Background And Objectives: Dimensional response is an unmet need in second lines of advanced soft tissue sarcomas (STS). Indeed, the three approved drugs, pazopanib, trabectedin, and eribulin, achieved an overall response rate (ORR) of less than 10%. This fact potentially hinders the options for fast symptomatic relief or surgical rescue.
View Article and Find Full Text PDFArticle Synopsis
- * Pazopanib is the most commonly used systemic therapy for GCTs, showing disease control in 80% of patients and an objective response in 40% during a median treatment time of seven months.
- * Molecular studies indicate that the effectiveness of pazopanib may be linked to genetic factors that enhance certain signaling pathways, and while there are other targeted therapies, pazopanib remains a promising treatment option for advanced GCTs.
Coronavirus disease 2019 (COVID-19) pandemic is affecting a high percentage of the population at an unprecedented rate. Cancer patients comprise a subgroup especially vulnerable to this infection. Herein, we present a prospective analysis of epidemiological, clinical, radiological and laboratory data of consecutive adult cancer patients seen in the Clínico San Carlos University Hospital (Madrid, Spain), and admitted to hospital and tested for COVID-19 between 21 February 2020 and 8 May 2020 due to clinical suspicion of infection.
View Article and Find Full Text PDF